Drug Trial Radar · NCT04952610
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Dec 13, 2021
Primary completion
Apr 10, 2026
Study completion Apr 10, 2026
Sponsor
- Lead sponsor
- Milestone Pharmaceuticals Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Open Label Extension study will enable eligible patients with Paroxysmal Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone Pharmaceuticals clinical trial of etripamil NS for PSVT, to access continued treatment with etripamil NS, Patients who experienced any significant safety issues during participation period in a previous clinical trial of etripamil NS, as per Investigator's assessment , are excluded. This study will be conducted by Investigators who previously participated in a Milestone Pharmaceuticals clinical trial and are trained on the use of etripamil NS.
Conditions
- Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS 70 mgDrug
Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
Aptar Pharma Nasal Spray Bidose SystemDevice
Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety of self-administered etripamil Nasal Spray (NS) for treatment of episodes of PSVT outside of the clinical setting as assessed by patient-reported adverse events.Time frame: Up to 3 years
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
Site # 0160
Little Rock, Arkansas
Site # 1023
Vista, California
Site # 1083
West Hills, California
Site # 0102
Atlanta, Georgia
Site # 0137
Macon, Georgia
Site # 1115
Coeur d'Alene, Idaho
Site # 0149
Fort Wayne, Indiana
Site # 1025
West Des Moines, Iowa
Site # 1007
Salisbury, Maryland
Site # 0166
Lansing, Michigan
Site # 0114
New York, New York
Site # 1024
Canton, Ohio
Site # 0110
Toledo, Ohio
Site # 1123
Corvallis, Oregon
Site # 0105
Yardley, Pennsylvania
Site # 0122
Rapid City, South Dakota
Site # 1047
Austin, Texas
Site # 0213
Victoria, British Columbia, Canada
Site # 0210
Halifax, Nova Scotia, Canada
Site # 2006
Oshawa, Ontario, Canada
Site # 0204
Toronto, Ontario, Canada
Site # 0203
Montreal, Quebec, Canada
Site # 0205
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.